Efficacy and safety of CD30-targeted chimeric antigen receptor T-cell therapy for lymphoma: a meta-analysis
Jixiang Shi, Cong Lu, Chao Song, Qian Wang · 2026
Read Efficacy and safety of CD30-targeted chimeric antigen receptor T-cell therapy for lymphoma: a meta-analysis by Jixiang Shi, Cong Lu, Chao Song, Qian Wang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13386688.txt.
Description
Jixiang Shi's team pooled trials of CD30-targeted CAR-T therapy for lymphoma, in a 2026 meta-analysis. Whether CD30 CAR-T benefits lymphoma patients remained controversial. The team searched Web of Science, PubMed, Embase, and Cochrane Library to March 2025 and pooled single-arm proportions from seven studies covering 102 cases.
Pooled complete response reached 43.5 percent, partial response 17.5 percent, stable disease 17.8 percent, and progressive disease 10.7 percent. The overall response pattern supports CD30 CAR-T as an active option for relapsed lymphoma, while heterogeneity and small numbers temper conclusions. Larger trials must confirm benefit and safety.
Catalog record
| CREATOR | Jixiang Shi, Cong Lu, Chao Song, Qian Wang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |